𝗔𝗵𝗲𝗮𝗱 𝗼𝗳 𝘁𝗼𝗺𝗼𝗿𝗿𝗼𝘄’𝘀 𝗮𝘂𝗰𝘁𝗶𝗼𝗻 𝗶𝗻 𝗣𝗮𝗿𝗶𝘀. 𝗗𝗿 𝗖𝗵𝗲 𝗖𝗼𝗻𝗻𝗼𝗻 pictured at Drouot with 𝗠𝗶𝗰𝗵𝗮𝗹 𝗛𝗮𝗱𝗮𝘀, founder of 𝗘𝗻𝗳𝗶𝗻 𝗟𝗲𝘃𝗲́ and designer of the world’s first 𝗧-𝗥𝗲𝘅 𝗟𝗲𝗮𝘁𝗵𝗲𝗿™ handbag. drouot.com/en/auctions/futur… #TRex

Public viewing is now open at 𝗛ô𝘁𝗲𝗹 𝗗𝗿𝗼𝘂𝗼𝘁, giving visitors in Paris the opportunity to see the world’s first 𝗧-𝗥𝗲𝘅 𝗟𝗲𝗮𝘁𝗵𝗲𝗿™ handbag ahead of Thursday’s live auction. 📍 Hôtel Drouot 9, rue Drouot 75009 Paris, France drouot.com/en/l/33736207-bag…

𝗕𝗦𝗙 𝗘𝗻𝘁𝗲𝗿𝗽𝗿𝗶𝘀𝗲 𝗣𝗟𝗖 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝘀 𝗮 𝗹𝗮𝗻𝗱𝗺𝗮𝗿𝗸 𝗺𝗼𝗺𝗲𝗻𝘁 𝗳𝗼𝗿 𝗧-𝗥𝗲𝘅 𝗟𝗲𝗮𝘁𝗵𝗲𝗿™. The world’s first luxury handbag made from 𝗧-𝗥𝗲𝘅 𝗟𝗲𝗮𝘁𝗵𝗲𝗿™ has been officially featured in the upcoming auction catalogue by 𝗛𝗼̂𝘁𝗲𝗹 𝗗𝗿𝗼𝘂𝗼𝘁, the prestigious Paris-based auction house. Following a rigorous appraisal process, 𝗗𝗿𝗼𝘂𝗼𝘁 has set an official estimate of €500,000 for this world-first luxury asset. The auction is scheduled to take place on 11 June 2026, online and in person. This is a visible proof point for what 𝗕𝗦𝗙 𝗘𝗻𝘁𝗲𝗿𝗽𝗿𝗶𝘀𝗲 𝗣𝗟𝗖 and its subsidiary 𝗟𝗮𝗯-𝗚𝗿𝗼𝘄𝗻 𝗟𝗲𝗮𝘁𝗵𝗲𝗿 𝗟𝘁𝗱 are building: a new class of bioengineered luxury materials, designed beyond the limits of traditional animal-derived leather. Following its global reveal and public exhibition in Amsterdam, 𝗕𝗦𝗙 𝗘𝗻𝘁𝗲𝗿𝗽𝗿𝗶𝘀𝗲 𝗣𝗟𝗖 has seen increased inbound commercial interest, with 𝗟𝗚𝗟 now in preliminary discussions with global Tier-1 brands across luxury, sportswear and automotive sectors. Read the RNS at: bsfenterprise.com/link/rJKmp… Explore the BSF Enterprise PLC Group at bsfenterprise.com #BSFEnterprise #LabGrownLeather #TRexLeather #LuxuryDesign #LuxuryMaterials #VML #TheOrganoidCompany #Drouot

𝗔𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲𝗱 𝗰𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹𝗶𝘀𝗮𝘁𝗶𝗼𝗻 𝗮𝗰𝗿𝗼𝘀𝘀 𝗮𝗹𝗹 𝘁𝗵𝗿𝗲𝗲 𝘀𝘂𝗯𝘀𝗶𝗱𝗶𝗮𝗿𝗶𝗲𝘀 This morning, 𝗕𝗦𝗙 𝗘𝗻𝘁𝗲𝗿𝗽𝗿𝗶𝘀𝗲 𝗣𝗟𝗖 issued a strategic update outlining progress across its three high-growth subsidiaries. The activities are structured to accelerate commercialisation, with near-term milestones across 𝗟𝗮𝗯-𝗚𝗿𝗼𝘄𝗻 𝗟𝗲𝗮𝘁𝗵𝗲𝗿 𝗟𝘁𝗱, 𝗞𝗲𝗿𝗮𝘁𝗼 𝗟𝘁𝗱 and 𝟯𝗗 𝗕𝗶𝗼-𝗧𝗶𝘀𝘀𝘂𝗲𝘀 𝗟𝘁𝗱. Key highlights include: • 𝗟𝗮𝗯-𝗚𝗿𝗼𝘄𝗻 𝗟𝗲𝗮𝘁𝗵𝗲𝗿 𝗟𝘁𝗱 progressing towards the June 11 Paris auction of the world-first 𝗧-𝗥𝗲𝘅 𝗟𝗲𝗮𝘁𝗵𝗲𝗿™ handbag, with an independent spin-out pathway planned post-catalyst to support production scale-up • 𝗞𝗲𝗿𝗮𝘁𝗼 𝗟𝘁𝗱 advancing LiQD Cornea clinical and commercial milestones, with veterinary sales targeted for early 2027 and a subsidiary-level self-funding spin-out planned post-catalyst • 𝟯𝗗 𝗕𝗶𝗼-𝗧𝗶𝘀𝘀𝘂𝗲𝘀 𝗟𝘁𝗱 building commercial momentum through 𝗖𝘆𝘁𝗼𝗕𝗼𝗼𝘀𝘁™ REVIVE and 𝗖𝗶𝘁𝘆-𝗠𝗶𝘅®, including significant customer order growth over a recent three-month period and a secured commercial pipeline of £500,000 The Board believes 2026 represents a critical period for 𝗕𝗦𝗙 𝗘𝗻𝘁𝗲𝗿𝗽𝗿𝗶𝘀𝗲 𝗣𝗟𝗖, as the Group moves from R&D towards commercial and clinical-stage activity. Read the full announcement here: tinyurl.com/t89nzzxb Explore the BSF Enterprise PLC Group at bsfenterprise.com #BSFEnterprise #BSFA #BSFAF #Biotech #IndustrialTissueEngineering #LabGrownLeather #TRexLeather #Kerato #3DBioTissues

𝗧-𝗥𝗲𝘅 𝗟𝗲𝗮𝘁𝗵𝗲𝗿™ The campaign has now recorded coverage across fashion, luxury, design, science, business and mainstream media: • 4.63B combined audience reach • 21.5M estimated views • 549 pieces of coverage For 𝗕𝗦𝗙 𝗘𝗻𝘁𝗲𝗿𝗽𝗿𝗶𝘀𝗲 𝗣𝗟𝗖, this is more than publicity. It is a visible proof point for the Group’s wider strategy in 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝗶𝗮𝗹 𝗧𝗶𝘀𝘀𝘂𝗲 𝗘𝗻𝗴𝗶𝗻𝗲𝗲𝗿𝗶𝗻𝗴. Through 𝗟𝗮𝗯-𝗚𝗿𝗼𝘄𝗻 𝗟𝗲𝗮𝘁𝗵𝗲𝗿 𝗟𝘁𝗱, the Group is showing how biology can move beyond imitation and into engineered exclusivity. 𝗧-𝗥𝗲𝘅 𝗟𝗲𝗮𝘁𝗵𝗲𝗿™ is not the end product. It is a proof point. A demonstration that cultivated, bioengineered materials can create new possibilities for luxury, advanced materials and future high-value markets. For investors, the opportunity lies in the platform behind the headline. 𝗕𝗦𝗙 𝗘𝗻𝘁𝗲𝗿𝗽𝗿𝗶𝘀𝗲 𝗣𝗟𝗖 LSE: BSFA | OTCQB: BSFAF – Explore the BSF Enterprise PLC Group at bsfenterprise.com #BSFEnterprise #BSFA #BSFAF #LabGrownLeather #TRexLeather #TRex #Biotech #AdvancedMaterials #LuxuryMaterials #TissueEngineering #VML #TheOrganoidCompany

𝗕𝗦𝗙 𝗘𝗻𝘁𝗲𝗿𝗽𝗿𝗶𝘀𝗲 𝗣𝗟𝗖 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝘀 𝗻𝗲𝘄 𝗰𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗮𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁 𝗶𝗻 𝗰𝘂𝗹𝘁𝗶𝘃𝗮𝘁𝗲𝗱 𝗺𝗲𝗮𝘁 𝗕𝗦𝗙 𝗘𝗻𝘁𝗲𝗿𝗽𝗿𝗶𝘀𝗲 𝗣𝗟𝗖 has announced that its subsidiary 𝟯𝗗 𝗕𝗶𝗼-𝗧𝗶𝘀𝘀𝘂𝗲𝘀 𝗟𝗶𝗺𝗶𝘁𝗲𝗱 (𝟯𝗗𝗕𝗧) has signed a 𝗳𝗶𝘃𝗲-𝘆𝗲𝗮𝗿 commercial supply agreement with 𝗦𝗲𝗮𝗪𝗶𝘁𝗵, a biotechnology company focused on cultivated meat. This agreement marks a clear step forward in the commercial rollout of 𝗖𝗶𝘁𝘆-𝗠𝗶𝘅®, 𝟯𝗗𝗕𝗧’s proprietary cell culture additive. What this means: 𝗖𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝘁𝗿𝗮𝗰𝘁𝗶𝗼𝗻 City-Mix® moves further into the global cultivated protein market 𝗥𝗲𝘃𝗲𝗻𝘂𝗲 𝘃𝗶𝘀𝗶𝗯𝗶𝗹𝗶𝘁𝘆 Approx. £300,000 contract value over five years 𝗥𝗲𝗮𝗹-𝘄𝗼𝗿𝗹𝗱 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 Supporting production of SeaWith’s Welldone™ cultivated beef 𝗖𝗼𝘀𝘁 𝗿𝗲𝗱𝘂𝗰𝘁𝗶𝗼𝗻 Up to 30% less reliance on expensive growth media 𝗦𝗰𝗮𝗹𝗲 𝗽𝗮𝘁𝗵𝘄𝗮𝘆 Supply volumes expected to grow alongside commercial production through 2030 This is not early-stage research. This is deployment into an active production pipeline. For 𝗕𝗦𝗙 𝗘𝗻𝘁𝗲𝗿𝗽𝗿𝗶𝘀𝗲, it reinforces a clear strategy: • Build enabling technologies • Partner with producers • Scale through commercial supply agreements The cultivated meat sector needs cost reduction to unlock scale. City-Mix® is now positioned as part of that solution. How quickly do you think cost efficiencies like this will accelerate market adoption? Check out the full announcement and join in with the conversation at: bsfenterprise.com/link/Pqnko… #BSFE #BSFA #BSFAF #CultivatedMeat #Biotech #CellCulture #FoodTech #Innovation

𝗕𝗦𝗙 𝗘𝗻𝘁𝗲𝗿𝗽𝗿𝗶𝘀𝗲 𝗣𝗟𝗖 announces a major milestone in the development of next-generation biological materials. 𝗪𝗼𝗿𝗹𝗱’𝘀 𝗙𝗶𝗿𝘀𝘁 𝗧𝗮𝗻𝗻𝗮𝗯𝗹𝗲 𝗟𝗮𝗯-𝗚𝗿𝗼𝘄𝗻 𝗔𝟰 𝗦𝗸𝗶𝗻 This breakthrough demonstrates that 𝗟𝗮𝗯-𝗚𝗿𝗼𝘄𝗻 𝟭𝟬𝟬% 𝗥𝗲𝗮𝗹 𝗟𝗲𝗮𝘁𝗵𝗲𝗿, a wholly-owned subsidiary of BSFE, can now be cultivated at dimensions and thickness relevant to luxury manufacturing. The milestone confirms that the Company’s proprietary 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗧𝗶𝘀𝘀𝘂𝗲 𝗘𝗻𝗴𝗶𝗻𝗲𝗲𝗿𝗶𝗻𝗴 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺 (𝗔𝗧𝗘𝗣™) is capable of producing scaffold-free biological materials that replicate the structural and performance characteristics of traditional hide. 𝗞𝗲𝘆 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 • 𝗔𝟰-𝘀𝗶𝘇𝗲𝗱 𝘁𝗮𝗻𝗻𝗮𝗯𝗹𝗲 𝘀𝗸𝗶𝗻 𝗽𝗿𝗼𝗱𝘂𝗰𝗲𝗱 at industrially relevant thickness (~2mm) • 𝗦𝗰𝗮𝗹𝗮𝗯𝗹𝗲 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗽𝗿𝗼𝗰𝗲𝘀𝘀 𝗲𝘀𝘁𝗮𝗯𝗹𝗶𝘀𝗵𝗲𝗱 after six months of optimisation • 𝗦𝗰𝗮𝗳𝗳𝗼𝗹𝗱-𝗳𝗿𝗲𝗲 𝗮𝗿𝗰𝗵𝗶𝘁𝗲𝗰𝘁𝘂𝗿𝗲 allowing cells to self-organise into natural leather structures • 𝗭𝗲𝗿𝗼-𝘄𝗮𝘀𝘁𝗲 𝗴𝗲𝗼𝗺𝗲𝘁𝗿𝘆, enabling skins to be cultivated to specification rather than cut from irregular hides The successful tanning of this cultivated skin marks a critical step toward the commercialisation of 𝗘𝗹𝗲𝗺𝗲𝗻𝘁𝗮𝗹™, the product series being developed by 𝗟𝗮𝗯-𝗚𝗿𝗼𝘄𝗻 𝗟𝗲𝗮𝘁𝗵𝗲𝗿 𝗟𝘁𝗱. It also underpins the upcoming public showcase of 𝗧-𝗥𝗲𝘅 𝗟𝗲𝗮𝘁𝗵𝗲𝗿™, scheduled for 𝟮 𝗔𝗽𝗿𝗶𝗹 𝟮𝟬𝟮𝟲, where the technology platform will be demonstrated to partners, brands, and investors. Leather is no longer limited by what animals we raise, but by what biology we can design. 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗥𝗡𝗦 𝗵𝗲𝗿𝗲: tinyurl.com/3hx59tzf bsfenterprise.com #LabGrownLeather #ElementalLeather #TRex #TRexLeather #Biotechnology #LuxuryMaterials #LabGrownLeather #IndustrialTissueEngineering #BSFA #BSFAF

The global leather market exceeds $48B. The corneal transplant market is projected to reach $1.86B by 2033. The wider bio-based materials market and related adjacent markets now surpass $130B. These are established industries in structural transition, where scale depends on tighter process control, consistency and manufacturability. 𝗕𝗦𝗙 𝗘𝗻𝘁𝗲𝗿𝗽𝗿𝗶𝘀𝗲 𝗣𝗟𝗖 (BSFA) (BSFAF) has built its strategy around one clear thesis: 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝗶𝗮𝗹 𝗧𝗶𝘀𝘀𝘂𝗲 𝗘𝗻𝗴𝗶𝗻𝗲𝗲𝗿𝗶𝗻𝗴 It is a business and technology framework to move tissue engineering from small, bespoke lab work into large-scale, cost-effective manufacturing. 𝗧𝗵𝗲 𝗰𝗼𝗿𝗲 𝗽𝗿𝗶𝗻𝗰𝗶𝗽𝗹𝗲 is simple: scale over bespoke. We manufacture lab-grown alternatives to animal and human tissues at a scale that can compete with agriculture, donor supply and traditional leather production. This approach underpins the Group’s core subsidiaries: 𝗟𝗮𝗯-𝗚𝗿𝗼𝘄𝗻 𝗟𝗲𝗮𝘁𝗵𝗲𝗿 𝗟𝘁𝗱 (LGL), 𝗞𝗲𝗿𝗮𝘁𝗼 𝗟𝘁𝗱 (Kerato) and 𝟯𝗗 𝗕𝗶𝗼-𝗧𝗶𝘀𝘀𝘂𝗲𝘀 𝗟𝘁𝗱 (3DBT). 𝗟𝗮𝗯-𝗚𝗿𝗼𝘄𝗻 𝗟𝗲𝗮𝘁𝗵𝗲𝗿 𝗟𝘁𝗱 (LGL) applies its proprietary 𝗔𝗧𝗘𝗣™ platform to produce 𝗟𝗮𝗯-𝗚𝗿𝗼𝘄𝗻 𝟭𝟬𝟬% 𝗥𝗲𝗮𝗹 𝗟𝗲𝗮𝘁𝗵𝗲𝗿 for high-value luxury and advanced materials markets, with traceability and far less reliance on animal supply chains. 𝗔𝗧𝗘𝗣™ is scaffold-free, enabling cells to organise and build natural architecture that integrates with downstream processing, with control, repeatability and scalability. 𝗞𝗲𝗿𝗮𝘁𝗼 𝗟𝘁𝗱 (Kerato) develops bio-engineered corneal solutions to reduce reliance on donor tissue, using an engineered “bridge” tissue that supports the patient’s own corneal repair in the body. 𝟯𝗗 𝗕𝗶𝗼-𝗧𝗶𝘀𝘀𝘂𝗲𝘀 𝗟𝘁𝗱 (3DBT) supports cultivated tissue development and supplies cost-saving tools to other companies. 𝗖𝗶𝘁𝘆-𝗠𝗶𝘅® and 𝗖𝘆𝘁𝗼𝗕𝗼𝗼𝘀𝘁™ improve cell growth efficiency and reduce reliance on costly growth factors, helping partners scale and cut media costs. This is already translating into market engagement: strategic programmes with global luxury houses, collaboration with 𝗩𝗠𝗟 and 𝗧𝗵𝗲 𝗢𝗿𝗴𝗮𝗻𝗼𝗶𝗱 𝗖𝗼𝗺𝗽𝗮𝗻𝘆 on LGL’s 𝗘𝗹𝗲𝗺𝗲𝗻𝘁𝗮𝗹 𝗫™ and 𝗧-𝗥𝗲𝘅 𝗟𝗲𝗮𝘁𝗵𝗲𝗿™ and commercial sales of 3DBT’s media additives. 𝗧-𝗥𝗲𝘅 𝗟𝗲𝗮𝘁𝗵𝗲𝗿™ has attracted international media attention because it shows programmable biology in practice: we can design and specify material characteristics, not just reproduce what already exists. Taken together, 𝗕𝗦𝗙 𝗘𝗻𝘁𝗲𝗿𝗽𝗿𝗶𝘀𝗲 𝗣𝗟𝗖 is emerging as a leading publicly listed company in industrial tissue engineering, deploying this approach across multiple large addressable markets with differentiated intellectual property and growing commercial traction. 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝗶𝗮𝗹 𝗧𝗶𝘀𝘀𝘂𝗲 𝗘𝗻𝗴𝗶𝗻𝗲𝗲𝗿𝗶𝗻𝗴 powers this portfolio. Explore the BSF Enterprise PLC Group at bsfenterprise.com #BSFEnterprise #TRex #TRexLeather #TissueEngineering #Investors #BSFA #BSFAF